PulseAugur
EN
LIVE 11:45:00

China's AI drug design firms secure $75B in deals amid US scrutiny

By PulseAugur Editorial · [1 sources] ·

Chinese AI-driven drug design companies are experiencing a surge in global dealmaking, with out-licensing deals valued at $75 billion in the first five months of 2026. This represents a significant increase from pre-2020 levels and a substantial jump from the previous year. Despite increasing scrutiny from the US on Chinese biotech firms, companies like Metis TechBio are securing substantial upfront payments and potential milestone payments for their AI-powered drug candidates, such as MTS-128 for cancer treatment. AI

IMPACT Accelerates global adoption of AI in pharmaceutical research and development, particularly for novel drug candidates.

RANK_REASON Significant increase in deal value and volume for Chinese AI drug design firms, indicating a major industry trend. [lever_c_demoted from significant: ic=1 ai=0.7]

Read on SCMP — Tech →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

China's AI drug design firms secure $75B in deals amid US scrutiny

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Significant increase in deal value and volume for Chinese AI drug design firms, indicating a major industry trend. [lever_c_demoted from significant: ic=1 ai=0.7]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, policy
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
High
Clearly on-topic for AI-industry coverage.
Story freshness
60 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. SCMP — Tech TIER_1 English(EN) · Julie Zhang ·

    China AI drug-design deals swell as US scrutiny mounts

    Riding a wave of booming cross-border dealmaking, China’s AI-driven drug-design firms are charging onto the global stage despite Washington’s growing scrutiny of Chinese biotech firms. The value of out-licensing deals struck by Chinese biotech companies with top global multinatio…

RELATED ENTITIES

RELATED TOPICS